Stock Quote
Xtent, Inc. (XTNT.OQ) (NASDAQ Stock Exchange Global Market)
$0.40
23 Oct 2009
+0.00%
$0.40
--
18,040
$0.40
$0.40
$2.69
$0.15
0.56
0
No news stories for this company within the last 30 days.
XTNT.OQ
More News
| Press Releases
| Key Developments
| Name | Current Position | Compensation |
|---|---|---|
| Plain, Henry | Chairman of the Board | -- |
| Casciaro, Gregory | President, Chief Executive Officer, Director | 1,132,810 |
| Kahlenberg, Timothy | Chief Financial Officer | 812,074 |
Profile
XTENT, Inc. is a development-stage medical device company focused on developing and commercializing drug eluting stent (DES), systems for the treatment of coronary artery disease (CAD). The DES systems are designed to enable physicians to customize both length and diameter of the stent at the site... Full Description
Company Address
Xtent, Inc.
125 Constitution Drive
Menlo Park CA 94025
P: +1650.4759400
F: +1650.4759401
125 Constitution Drive
Menlo Park CA 94025
P: +1650.4759400
F: +1650.4759401
Analyst Research
Performance of Key Competitors
| Company | Price | Change |
|---|---|---|
| Abbott Laboratories | $54.41 | +0.17 |
| Boston Scientific Corporation | $8.64 | +0.08 |
| Johnson & Johnson | $63.30 | +0.12 |
| XTNT.OQ | Industry | |
|---|---|---|
| P/E(TTM) | -- | 7.99 |
| P/S(TTM) | -- | 0.50 |
| ROI(TTM) | -120.42 | 1.04 |
| ROE(TTM) | -120.42 | 1.62 |
| Consensus Recommendation | |
|---|---|
| EPS Est. (Current Period) | -- |
| EPS Est. (Current Year) | -- |
| Total Revenue | $0.00M |
| Net Income | $-2.12M |
| EPS | $-0.09 |
